drugset / Trial / NCT00803374
Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine if BMS-663513 administered in combination with ipilimumab to patients with advanced malignant melanoma is safe and tolerable
Timeline
- Start
- 2010-11
- Primary completion
- 2012-07
- Completion
- 2013-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Urelumab | Monoclonal antibody | 0.1 mg/kg | Intravenous |
| Subject | Urelumab | Monoclonal antibody | 0.3 mg/kg | Intravenous |
| Subject | Urelumab | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | Urelumab | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | Urelumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Background | Ipilimumab | Monoclonal antibody | 10 mg/kg | Intravenous |